» Articles » PMID: 27940962

RB Localizes to DNA Double-strand Breaks and Promotes DNA End Resection and Homologous Recombination Through the Recruitment of BRG1

Overview
Journal Genes Dev
Specialty Molecular Biology
Date 2016 Dec 13
PMID 27940962
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The retinoblastoma (RB) tumor suppressor is recognized as a master regulator that controls entry into the S phase of the cell cycle. Its loss leads to uncontrolled cell proliferation and is a hallmark of cancer. RB works by binding to members of the E2F family of transcription factors and recruiting chromatin modifiers to the promoters of E2F target genes. Here we show that RB also localizes to DNA double-strand breaks (DSBs) dependent on E2F1 and ATM kinase activity and promotes DSB repair through homologous recombination (HR), and its loss results in genome instability. RB is necessary for the recruitment of the BRG1 ATPase to DSBs, which stimulates DNA end resection and HR. A knock-in mutation of the ATM phosphorylation site on E2F1 (S29A) prevents the interaction between E2F1 and TopBP1 and recruitment of RB, E2F1, and BRG1 to DSBs. This knock-in mutation also impairs DNA repair, increases genomic instability, and renders mice hypersensitive to IR. Importantly, depletion of RB in osteosarcoma and breast cancer cell lines results in sensitivity to DNA-damaging drugs, which is further exacerbated by poly-ADP ribose polymerase (PARP) inhibitors. We uncovered a novel, nontranscriptional function for RB in HR, which could contribute to genome instability associated with RB loss.

Citing Articles

The Role of SWI/SNF Complex in Bladder Cancer.

Lei Z, Han Y, Liao J, Li X, Su Q, Yang Z J Cell Mol Med. 2025; 29(1):e70348.

PMID: 39779467 PMC: 11710939. DOI: 10.1111/jcmm.70348.


The significance of in multiple myeloma.

Wang Y, Yang R, Liu R, Yang R, Lin Z, He A Front Immunol. 2024; 15():1415972.

PMID: 39664374 PMC: 11631746. DOI: 10.3389/fimmu.2024.1415972.


SWItch/Sucrose Nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy.

Gu Y, Lai S, Yang J, Zhang J, Fan X, Zheng Q Transl Lung Cancer Res. 2024; 13(10):2660-2672.

PMID: 39507018 PMC: 11535837. DOI: 10.21037/tlcr-24-339.


Bivalent chromatin accommodates survivin and BRG1/SWI complex to activate DNA damage response in CD4 cells.

Chandrasekaran V, Andersson K, Erlandsson M, Li S, Olsson T, Garcia-Bonete M Cell Commun Signal. 2024; 22(1):440.

PMID: 39261837 PMC: 11389452. DOI: 10.1186/s12964-024-01814-4.


Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.

Telli M, Litton J, Beck J, Jones J, Andersen J, Mina L Breast Cancer. 2024; 31(5):886-897.

PMID: 38869771 PMC: 11341741. DOI: 10.1007/s12282-024-01603-4.


References
1.
Zhang B, Wang E, Dai H, Shen J, Hsieh H, Lu X . Phosphorylation of the BRCA1 C terminus (BRCT) repeat inhibitor of hTERT (BRIT1) protein coordinates TopBP1 protein recruitment and amplifies ataxia telangiectasia-mutated and Rad3-related (ATR) Signaling. J Biol Chem. 2014; 289(49):34284-95. PMC: 4256359. DOI: 10.1074/jbc.M114.587113. View

2.
Carey M, Peterson C, Smale S . Chromatin immunoprecipitation (ChIP). Cold Spring Harb Protoc. 2010; 2009(9):pdb.prot5279. DOI: 10.1101/pdb.prot5279. View

3.
Malewicz M, Perlmann T . Function of transcription factors at DNA lesions in DNA repair. Exp Cell Res. 2014; 329(1):94-100. DOI: 10.1016/j.yexcr.2014.08.032. View

4.
Wilson B, Roberts C . SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011; 11(7):481-92. DOI: 10.1038/nrc3068. View

5.
Knudsen E, Knudsen K . Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2009; 8(9):714-24. PMC: 2914856. DOI: 10.1038/nrc2401. View